Clinical Trials Browser

Phase 1 × OTHER × Vemurafenib × Clear all

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT01787500 2025-09-09

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Noonan syndrome 3, Neoplasm Metastasis, Colorectal Neoplasms

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1 Completed

8 enrolled 8 charts

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT02145910 2025-05-02

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Phase 1 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Completed

Melanoma, Skin Neoplasms

NCT05019534 2022-05-19

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

NCT02818023 2022-01-03

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01636622 2020-06-18

Study of Vemurafenib, Carboplatin, and Paclitaxel

Phase 1 Completed

Lymphoma

NCT01596140 2020-06-04

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Phase 1 Completed

Other solid neoplasm

Advanced Cancer

NCT01897116 2020-05-29

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Phase 1 Completed

Melanoma

NCT01603212 2019-05-21

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Phase 1 Completed

Melanoma

NCT02068079 2019-01-30

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Phase 1 Withdrawn

Melanoma

NCT01943422 2018-04-03

12-107

Phase 1 Completed

Melanoma

NCT01843738 2017-05-24

Radiation Use During Vemurafenib Treatment

Phase 1 Withdrawn

Melanoma

NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT01791309 2016-01-05

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms